For years, oncologists have observed a frustrating disparity in how patients respond to immunotherapy depending on where their mesothelioma is located. While those with pleural mesothelioma—cancer of the chest lining—sometimes see promising results from immune checkpoint inhibitors, patients with peritoneal mesothelioma—cancer of the abdominal lining—often face a much steeper uphill battle.
Latest research from Australia has identified the biological reason for this gap. The study, published in Scientific Reports, reveals that the peritoneal mesothelioma immunotherapy response is stifled by a specific, immune-suppressive tumor microenvironment. Essentially, the abdomen creates a “shield” around the cancer that prevents the immune system from recognizing and attacking the tumor, even when medication is used to trigger that response.
This discovery shifts the understanding of mesothelioma from a single disease with different locations to a condition where the anatomical site fundamentally alters the cancer’s genetic signature and its interaction with the host’s immune system. For clinicians, So that a “one size fits all” approach to immunotherapy is likely ineffective.
The Role of the Tumor Microenvironment
To understand these findings, it is necessary to look at the tumor microenvironment (TME). The TME is not just the cancer cells themselves, but the surrounding landscape of blood vessels, immune cells, and signaling molecules. In many cancers, the TME can be “hot,” meaning it is infiltrated by T-cells that are ready to fight. In other cases, the TME is “cold,” acting as a sanctuary where the tumor hides from the immune system.
The Australian research team tested this by implanting identical mesothelioma cells into mice in three distinct locations: the pleural cavity (chest), the peritoneal cavity (abdomen), and subcutaneously (under the skin). Because the cells were identical, any difference in growth or treatment response could be attributed solely to the location.
The results were stark. Tumors grown under the skin were the smallest and responded most effectively to immune checkpoint therapy. In contrast, tumors in the abdomen were largely unresponsive to the same treatment. The researchers found that the peritoneal location induced a specific gene signature associated with immune evasion, effectively “switching off” the body’s natural defenses.
Comparing Chest and Abdominal Cancer Responses
While both pleural and peritoneal tumors grew to similar sizes and displayed aggressive behavior, their relationship with the immune system differed significantly. The study found that pleural tumors showed a much higher concentration of immune cells clustering around the malignancy. This suggests that the chest environment is more permissive to immune infiltration, explaining why pleural mesothelioma patients often show better responses to immunotherapy treatments in clinical settings.
The aggressiveness of the tumors also varied by location. Peritoneal tumors were observed spreading early to the liver and pancreas. Pleural tumors, meanwhile, tended to invade the diaphragm and heart. Despite these different paths of invasion, the lack of immune cell clustering in the abdomen remained the primary driver of treatment failure.
| Location | Immune Cell Presence | Therapy Response | Primary Invasion Sites |
|---|---|---|---|
| Subcutaneous | High | Effective | N/A (Localized) |
| Pleural (Chest) | Moderate to High | Variable/Responsive | Heart, Diaphragm |
| Peritoneal (Abdomen) | Low (Suppressive) | Poor/Resistant | Liver, Pancreas |
Moving Toward Combination Therapy
The realization that the abdominal environment is actively suppressing the immune response opens a new door for treatment strategies. If the problem is a “cold” microenvironment, the solution may be to “heat it up” before administering checkpoint inhibitors.
Researchers suggest that future protocols for peritoneal mesothelioma may require combination therapies. This would involve using a primary drug to reprogram the inactive immune cells in the abdomen—essentially “waking them up”—followed by immunotherapy to direct those cells to attack the tumor. Recent advancements in oncology have shown that certain agents can shift the TME from a tumor-supporting state to a tumor-fighting state, a strategy that could potentially overcome the resistance seen in abdominal cases.
This approach would move the field away from the current standard of treating all mesothelioma similarly, regardless of location, and toward a more personalized, site-specific oncology model.
What This Means for Patients
For patients and families, this research provides a critical explanation for why some therapies fail despite appearing successful in other types of mesothelioma. It validates the need for specialized clinical trials that focus exclusively on the peritoneal variety of the disease rather than grouping all mesothelioma patients together.
By identifying the specific gene signatures that lead to immunotherapy resistance, scientists can now develop biomarkers to predict which patients are likely to respond to current treatments and which would benefit more from experimental combination trials. This precision medicine approach aims to reduce the time patients spend on ineffective treatments, allowing them to move more quickly to therapies that align with their specific tumor microenvironment.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should consult with a board-certified oncologist to discuss treatment options and clinical trial eligibility.
The next phase of this research will likely focus on identifying the specific molecules responsible for the peritoneal “shield.” Once these targets are confirmed, pharmaceutical development can begin on the “priming” agents needed to make immunotherapy viable for abdominal mesothelioma patients. Further updates are expected as these findings move from animal models into human clinical trial designs.
We invite readers to share their thoughts or experiences with immunotherapy in the comments below, or share this article with others who may find this research helpful.
